Orchid Pharma Limited announced that its Scheme of Amalgamation with Dhanuka Laboratories Limited has become effective as of July 10, 2026. Dhanuka Laboratories has been dissolved without being wound up. The authorized share capital of Orchid Pharma has been increased, and a record date of July 23, 2026, has been fixed for share issuance. The share exchange ratio is set at 161 equity shares of Orchid Pharma for every 5 equity shares of Dhanuka Laboratories.
Scheme Effectiveness and Dissolution
Orchid Pharma Limited (OPL) has officially declared that its Scheme of Amalgamation with Dhanuka Laboratories Limited (DLL) has been made effective from July 10, 2026. This significant milestone follows the fulfillment of all stipulated conditions under the scheme. Consequently, Dhanuka Laboratories Limited has been dissolved without undergoing a winding-up process, in adherence to the terms of the amalgamation agreement. The appointed date for this scheme is set as April 1, 2024.
Capital Restructuring and Share Allotment
In line with the effectiveness of the scheme, Orchid Pharma’s Memorandum of Association (MOA) has been updated. The authorized share capital has been increased through the amalgamation of DLL’s authorized capital. Clause V of OPL’s MOA now states an authorized share capital of Rs. 164,51,00,000, divided into 16,45,10,000 equity shares of Rs. 10 each.
A record date has been fixed for Thursday, July 23, 2026, to identify the shareholders of Dhanuka Laboratories who will be issued shares in the amalgamated company. This determination is made in consultation with Dhanuka Laboratories, as per SEBI Listing Regulations.
Share Exchange Ratio Detailed
The approved share exchange ratio under the amalgamation scheme is as follows: For every 5 fully paid-up equity shares of face value INR 100 each held in Dhanuka Laboratories Limited, members will receive 161 fully paid-up equity shares of face value INR 10 each in Orchid Pharma Limited.
Source: BSE
